非奈利酮用于射血分数改善的心力衰竭:FINEARTS-HF随机临床试验
FINEARTS-HF预设分析纳入6001例LVEF≥40%的心衰患者,其中273例有既往LVEF<40%病史(HFimpEF)。中位随访2.6年,HFimpEF患者主要终点事件率数值更高但校正后无统计学差异;非奈利酮治疗效应一致,HFimpEF绝对风险降低更大(9.2 vs 2.5/100患者年)。
要点
- HFimpEF患者仍面临较高心血管事件风险,需持续管理。
- 非奈利酮在HFimpEF与LVEF持续≥40%患者中治疗效应一致。
- HFimpEF患者绝对风险降低更大,但低血压风险倾向更高。
核心结论
- HFimpEF患者心血管事件风险仍高,LVEF改善后仍需持续管理。
- 非奈利酮在HFimpEF患者中的治疗获益与整体射血分数保留心衰人群一致。
研究设计与样本
- FINEARTS-HF随机临床试验的预设分析,纳入6001例LVEF≥40%、NYHA II-IV级、利钠肽升高的心衰患者。
- 273例(5%)有既往LVEF<40%病史,中位既往LVEF为35%(IQR 30%-37%),中位改善12%(IQR 8%-17%)。
- 干预为非奈利酮(滴定至20 mg或40 mg)或安慰剂,中位随访2.6年。
主要发现
- HFimpEF患者主要终点(心血管死亡和恶化心衰事件复合)发生率为21.4/100患者年,LVEF持续≥40%者为16.0/100患者年。
- HFimpEF患者绝对风险降低更大(9.2 vs 2.5/100患者年)。
- HFimpEF患者接受非奈利酮治疗时低血压倾向更多,其余安全性相似。
临床怎么用
- 对HFimpEF患者应认识到其残余心血管风险,不应因LVEF改善而停止管理。
- 非奈利酮可用于HFimpEF患者以降低心血管事件风险,但需关注低血压。
局限性
- HFimpEF亚组样本量较小(273例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) less than 40% who experience LVEF improvement to 40% or higher (HFimpEF) may still face residual risks. OBJECTIVE: To assess the clinical profiles, risk, and treatment response to finerenone in participants with HFimpEF. DESIGN, SETTING, AND PARTICIPANTS: A total of 6001 patients with HE, LVEF of 40% or higher, New York Heart Association class II to IV symptoms, and elevated natriuretic peptide levels, were enrolled between September 14, 2020, and January 10, 2023. Patients with a prior history of LVEF less than 40% were included. Data analysis was conducted between September 1 to December 10, 2024. INTERVENTION: Participants received finerenone (titrated to 20 mg or 40 mg) or placebo. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of cardiovascular (CV) death and total (first and recurrent) worsening HF events. RESULTS: Of the 6001 participants (mean [SD] age, 72 [9.7], years; 3269 male [55%]), 273 (5%) had a prior LVEF less than 40%. Among those with a prior LVEF of less than 40%, the median recorded prior LVEF was 35% [IQR, 30%-37%], with a median improvement of 12% [IQR, 8%-17%]. Over a median follow-up of 2.6 years, those with a history of LVEF of less than 40% experienced higher rates of the primary outcome of a composite of CV death and worsening of HF events (21.4 per 100 patient-years vs 16.0 per 100 patient-years) than did those whose LVEF was consistently 40% or higher. After adjustment for clinically relevant covariates; however, this rate ratio (RR) was not statistically different (absolute RR, 1.13; 95% CI, 0.85-1.49, P = .39). The treatment effect of finerenone on the primary outcome was consistent among those with a history of LVEF less than 40% and those with LVEF that was consistently 40% or higher (P for interaction = .36). Owing to higher baseline risk, the absolute risk reduction was greater among those with HFimpEF (9.2 vs 2.5 per 100 patient-years). Patients with HFimpEF tended to develop more hypotension with finerenone treatment, but otherwise, the safety profile of finerenone was similar in patients with and without previous LVEF less than 40%. CONCLUSIONS AND RELEVANCE: In this prespecified analysis of a randomized clinical trial, patients with HFimpEF remained at high risk of CV events, underscoring the need for continued management despite LVEF improvement. The treatment benefits of finerenone observed among the overall population of patients with HF with preserved EF were consistent among patients with HFimpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.
引用
- Pabon, Vardeny, Vaduganathan, et al. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40397470. doi:10.1001/jamacardio.2025.1101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。